Brief: Hepion Pharmaceuticals Announces Positive Results From Non-Alcoholic Fatty Liver Disease Trial
23/03/2021 11:33
March 23 (Reuters) - Hepion Pharmaceuticals Inc HEPA.O :
* HEPION PHARMACEUTICALS - ANNOUNCED POSITIVE RESULTS FROM
IN VIVO
STUDY OF CRV431 IN DIET-INDUCED ANIMAL MODEL OF NON-ALCOHOLIC
FATTY LIVER DISEASE
* HEPION PHARMACEUTICALS - FOUND CONSISTENT, STATISTICALLY
SIGNIFICANT ANTIFIBROTIC EFFECTS OF CRV431 IN EVERY ONE OF 9
INDIVIDUAL ANIMAL STUDIES OF FIBROSIS
Source text for Eikon: ID:nGNXYHcNz
Further company coverage: HEPA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement